Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
PTGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.22 - $60.60
Previous CloseN/A
Volume120.35K
Average Volume (3M)1.38M
Market Cap
$3.00B
Enterprise Value$2.16B
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)11.5
Beta1.08
Next Earnings
Apr 30, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.21
Shares Outstanding61,384,290
10 Day Avg. Volume1,227,876
30 Day Avg. Volume1,377,021
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.44
Price to Cash Flow (P/CF)-27.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.96
Enterprise Value/Ebitda8.46
Forecast
1Y Price Target
$67.80Price Target Upside44.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive data from the two Ph3 ICONIC ADVANCE 1&2 studies showed icotrokinra (JNJ-2113) was statistically superior to Sotyktu at key secondary endpoints.
Efficacy And SafetyEncouraging results from a presentation showed complete skin clearance from JNJ-2113 treatment with a good safety profile, supporting potential adoption upon approval.
Financial PerformanceThe $25M milestone payment on this positive data will further strengthen the balance sheet to support a runway through at least YE28 based on management's guidance.
Therapy PreferenceOnce-daily oral therapy is highly preferred by patients, and icotrokinra is anticipated to become a first-line therapy option without a black box warning.
Bears Say
Market CompetitionIL-23 agents are predicted to replace other medications including Stelara, similar to what happened in psoriasis.
Safety ConcernsMost AEs in the rusfertide study were grade 1-2 injection site reactions and all SAEs were deemed not drug related, but potential safety concerns remain.
---
Ownership Overview
1.78% Insiders
16.13% Mutual Funds
0.17% Other Institutional Investors
53.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $24.22 and its highest was $60.60 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $3.00B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 27 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Feb 21, 2025. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.388 by $0.592.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 61,384,290 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of $1.98 in its last earnings report, beating expectations of $1.388. Following the earnings report the stock price went up 0.676%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
---
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.80 (44.62% Upside)
$67.80 (44.62% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 81.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.16%
12-Months-Change
Fundamentals
Return on Equity
54.39%
Trailing 12-Months
Asset Growth
108.51%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
---
PTGX Stock 12 Month Forecast
Average Price Target
$67.80
▲(44.62% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Exelixis
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Enanta Pharmaceuticals
―
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
21/21 ratings generated profit
1 Year Average Return
+74.12%
reiterated a buy rating 24 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.12% per trade.
---